SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing a significant surge following its latest earnings, with bulls championing the success of 'Opendoor 2.0' as evidenced by improved unit economics, faster inventory turns, and a projected path to Q2 EBITDA profitability, despite ongoing bear sentiment focused on the reported GAAP losses and revenue decline.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as weaker-than-expected GDP and hotter inflation ignite community debates on rate cuts versus stagflation. Additionally, escalating geopolitical tensions and an awaited Supreme Court ruling on tariffs are contributing to market uncertainty and active discussion among traders.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL's stock is experiencing a dramatic decline after its NHS-Galleri trial missed its primary endpoint for reducing late-stage cancer diagnoses, igniting a fervent community debate where bears foresee further collapse while bulls claim the selloff is an overreaction, pointing to strong secondary data and a robust cash position.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Weaker-than-expected GDP and slightly elevated PCE data are fueling intense discussion around QQQ, with the community debating "stagflation" risks and market manipulation, yet many anticipate resilient bounces from dips amidst geopolitical tensions and broader economic uncertainty.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is actively discussed following successful wind tunnel testing of its STARLAUNCH I rocket with GE Aerospace and its upcoming NYSE opening bell ceremony. This news fuels robust bullish speculation around a potential short squeeze and broader sector growth, though some community members express skepticism regarding the company's financials and direct involvement in new defense contracts, hinting at possible dilution.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as strong IBSRELA growth and a patent extension to 2042 are overshadowed by a Q4 EPS miss and increased 2026 operating expenses, sparking community debate about near-term profitability and ongoing speculation about a potential acquisition.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as a battleground stock caught in the broader software sector sell-off, with an intense community debate raging over whether AI will disrupt its core business or enhance its strong financial performance and deeply entrenched user base. Despite robust cash flow and aggressive share buybacks, the stock continues to face significant downward pressure from short interest and market skepticism.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following the dual announcement of a $100 million public stock offering and a $100 million royalty funding agreement, sparking community discussion on whether the capital raise is strategic for future commercialization or represents significant dilution. While some investors express concern over immediate share dilution, others view the combined financing as a disciplined move to build runway and validate its pipeline ahead of crucial regulatory milestones, particularly the BLA submission for its lead prostate cancer candidate.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is at the center of investor conversation due to an impending Supreme Court decision on tariffs and intensified scrutiny surrounding the Epstein files following a notable international arrest. The community is actively debating economic reports and navigating ongoing concerns about potential stock dilution and market manipulation.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Tandem Diabetes Care Inc

Tandem Diabetes Care Inc. is trending after reporting stronger-than-expected Q4 earnings, which included a revenue beat and expanded gross margins, with the community actively discussing the positive implications of its strategic shift to a "pay as you go" revenue model for long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Truist reiterated $VRDN Buy-$40 and said, REVEAL-1 Topline Preview: Ele&#39; Positioned to Hit Proptosis Bar, after its KOLs check. 
$AMGN $IMVT - ROIV NVS  $ALMS $TRML 
Truist additionally said, Ahead of VRDN&#39;s REVEAL-1 topline for elegrobart (Ele&#39;, fka VRDN-003 SC), a half-life extended, SC, IGF-1Ra for active TED, we checked in with KOLs for updated views on Ele&#39; and the broader story. 
 
While management targets a 50-70% placebo-adjusted proptosis responder rate, physicians would accept the low end given the strong convenience advantage. 
 
Ele&#39; is seen as a potential &quot;game-changer&quot; particularly in chronic and low-CAS patients. 
 
A REVEAL-1 win would meaningfully de-risk REVEAL-2 in 2Q and support our ~ $1.3B peak revenue est. 
 
Our check-in on volatility surface and the options book for VRDN aligns with our positive views, NT and LT. Reiterate Buy, $40 PT.

Tom Dorsey

Evercore ISI⬆️ $VRDN&#39;s PT to $45 from $44 and reiterated at an Outperform rating. 
$AMGN $IMVT - $ROIV $NVS TEVA 
Here&#39;s what Evercore ISI said in its note: https://x.com/Quantumup1/status/2016502597268471892?s=20

Evercore ISI⬆️ $VRDN's PT to $45 from $44 and reiterated at an Outperform rating.$AMGN $IMVT - ROIV NVS TEVAEvercore ISI said in its note:The upcoming P3 subQ TED data for VRDN (1Q26) is one of the most important events for the company in the last couple years. But given the...

quantumup on X (formerly Twitter): "Evercore ISI⬆️ $VRDN's PT to $45 from $44 and reiterated at an Outperform rating.$AMGN $IMVT - ROIV NVS TEVAEvercore ISI said in its note:The upcoming P3 subQ TED data for VRDN (1Q26) is one of the most important eve...

StockTwits Web

Viridian Therapeutics Inc

AMGEN Inc.

Immunovant Inc

Roivant Sciences Ltd

Novartis AG

Quantumup

Alumis Inc.

Tourmaline Bio Inc

 Buy-$40 and said, REVEAL-1 Topline Preview: Ele' Positioned to Hit Proptosis Bar, after its KOLs check. 


 
Truist additionally said, Ahead of VRDN's REVEAL-1 topline for elegrobart (Ele', fka VRDN-003 SC), a half-life extended, SC, IGF-1Ra for active TED, we checked in with KOLs for updated views on Ele' and the broader story. 
 
While management targets a 50-70% placebo-adjusted proptosis responder rate, physicians would accept the low end given the strong convenience advantage. 
 
Ele' is seen as a potential "game-changer" particularly in chronic and low-CAS patients. 
 
A REVEAL-1 win would meaningfully de-risk REVEAL-2 in 2Q and support our ~ $1.3B peak revenue est. 
 
Our check-in on volatility surface and the options book for VRDN aligns with our positive views, NT and LT. Reiterate Buy, $40 PT.